Macquarie Group’s Atossa Therapeutics ATOS Stock Holding History

Macquarie Group’s Portfolio ATOS Stock Details ATOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-116	Closed	-$3	–	1918
2024 Q1	$3	Buy	+116	New	+$1.86K	﹤0.01%	1830
2019 Q1	–	Sell	-380	Closed	-$6K	–	1665
2018 Q4	$6K	Buy	+380	New	+$7.52K	﹤0.01%	2038

Other funds holding ATOS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Macquarie Group's ATOS Position: Q2 2024 in Review

Macquarie Group sold out of Atossa Therapeutics (ATOS) in Q2 2024, closing a stake of 116 shares — an estimated $3 sold.

Macquarie Group first reported a position in ATOS in Q4 2018 and held it in 2 quarters. The position peaked at $6K in Q4 2018. 77 funds tracked by Wall St. Rank hold ATOS as of Q2 2024.

Macquarie Group reported no remaining Atossa Therapeutics position as of Q2 2024 after selling out during the quarter.
Macquarie Group sold 116 Atossa Therapeutics shares in Q2 2024, an estimated $3.
Macquarie Group first reported a position in Atossa Therapeutics in Q4 2018 and held it in 2 quarters.
Macquarie Group's Atossa Therapeutics position peaked at $6K in Q4 2018.
77 funds tracked by Wall St. Rank held Atossa Therapeutics as of Q2 2024.

Based on Macquarie Group's 13F filing for Q2 2024, filed 9 Aug 2024.